Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Coya Therapeutics (COYA) Equity Average (2022 - 2025)

Coya Therapeutics' Equity Average history spans 4 years, with the latest figure at $27.8 million for Q3 2025.

  • For Q3 2025, Equity Average fell 17.35% year-over-year to $27.8 million; the TTM value through Sep 2025 reached $27.8 million, down 17.35%, while the annual FY2024 figure was $37.6 million, 176.09% up from the prior year.
  • Equity Average for Q3 2025 was $27.8 million at Coya Therapeutics, down from $30.8 million in the prior quarter.
  • Across five years, Equity Average topped out at $36.5 million in Q1 2025 and bottomed at -$6.9 million in Q4 2022.
  • The 4-year median for Equity Average is $25.3 million (2023), against an average of $19.7 million.
  • The largest annual shift saw Equity Average soared 5191.46% in 2023 before it fell 17.35% in 2025.
  • A 4-year view of Equity Average shows it stood at -$6.9 million in 2022, then skyrocketed by 432.52% to $22.9 million in 2023, then soared by 56.56% to $35.8 million in 2024, then fell by 22.34% to $27.8 million in 2025.
  • Per Business Quant, the three most recent readings for COYA's Equity Average are $27.8 million (Q3 2025), $30.8 million (Q2 2025), and $36.5 million (Q1 2025).